Literature DB >> 26820659

[Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours].

P Paffenholz1, D Pfister1, A Heidenreich2.   

Abstract

INTRODUCTION: Postchemotherapy residual tumour resection (PC-RTR) is an integral part of the multimodal therapy for advanced testicular germ cell tumours. Depending on the extent and localisation of the residual mass, PC-RTR may necessitate a multidisciplinary procedure (which should be planned preoperatively), to resolve even complex situations in an oncologically sound manner, with lower treatment-related morbidity The aim of article is to report on the interdisciplinary management of complex residual masses. PATIENTS AND METHODS: Of a total of 162 patients who underwent PC-RTR, 24 (17.8 %) patients underwent, in addition to a bilateral postchemotherapy retroperitoneal lymphadenectomy (PC-RPLND), complex adjunctive resections including the abdominal aorta, the inferior vena cava, or the thoracic/lumbar spine, and the neighbouring vessels (n = 15). We performed a retrospective analysis of treatment-associated complications according to the Clavien-Dindo classification and of progression-free, cancer-specific and overall survival.
RESULTS: Median patient age was 24.5 (18-52) years. All patients had an intermediate or poor prognosis according to the International Germ Cell Cancer Collaboration Group (IGCCCG). Median tumour diameter at the time of surgery was 18.6 (9.0-35) cm. In 5 patients 1-2 metastatic lumbar vertebral bodies were completely resected, stabilised and replaced by means of a cage. In 6 patients resection of the abdominal aorta/inferior vena cava with vascular prosthesis replacement was required owing to infiltration. In 2 patients the common iliac artery or vein was resected and replaced. In addition, retrocrural lymph nodes had to be resected in 5 patients and 3 patients required adjunctive nephrectomy. In another 4 patients the Whipple procedure was required owing to infiltration into the pancreas and/or duodenum. The median operating time was 7.8 (6-15) h, the median blood loss was around 1,450 (900-3,400) ml, and 2 Clavien-Dindo grade IVa complications occurred. Pathohistology revealed teratoma/vital cancer in 16/24 patients and scarring/necrosis in 8 patients. After a median follow-up of 2.5 years, 1 patient developed recurrent disease and 1 patient died of the disease.
CONCLUSIONS: Postchemotherapy, a few patients with advanced nonseminomas (NS) need complex residual tumour resection in an interdisciplinary setting, with a good functional and oncological outcome. Even the involvement of vascular vertebral structures does not constitute a contraindication for complete resection.

Entities:  

Keywords:  Aortic resection; Chemotherapy; Inferior vena cava replacement; Retroperitoneal lymphadenectomy; Testicular cancer

Mesh:

Year:  2016        PMID: 26820659     DOI: 10.1007/s00120-016-0031-7

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  28 in total

1.  Metastatic testicular cancer presenting as spinal cord compression: report of two cases.

Authors:  P M Arnold; C J Morgan; R A Morantz; D A Eckard; J J Kepes
Journal:  Surg Neurol       Date:  2000-07

2.  Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group.

Authors:  Christian Winter; David Pfister; Jonas Busch; Cigdem Bingöl; Ulrich Ranft; Mark Schrader; Klaus-Peter Dieckmann; Axel Heidenreich; Peter Albers
Journal:  Eur Urol       Date:  2011-11-07       Impact factor: 20.096

3.  Evaluation by magnetic resonance imaging of the inferior vena cava in patients with non-seminomatous germ cell tumours of the testis metastatic to the retroperitoneum.

Authors:  C S Ng; J E Husband; A R Padhani; M A Long; A Horwich; W F Hendry; D P Dearnaley
Journal:  Br J Urol       Date:  1997-06

4.  En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes.

Authors:  P A Nash; I Leibovitch; R S Foster; R Bihrle; R G Rowland; J P Donohue
Journal:  J Urol       Date:  1998-03       Impact factor: 7.450

5.  Repeat retroperitoneal lymphadenectomy in advanced testicular cancer.

Authors:  Axel Heidenreich; Carsten Ohlmann; Axel Hegele; Jörg Beyer
Journal:  Eur Urol       Date:  2005-01       Impact factor: 20.096

6.  Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection.

Authors:  S D Beck; R S Foster; R Bihrle; M O Koch; G R Wahle; J P Donohue
Journal:  J Urol       Date:  2001-05       Impact factor: 7.450

7.  Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer.

Authors:  Ashraf A Mosharafa; Richard S Foster; Michael O Koch; Richard Bihrle; John P Donohue
Journal:  J Urol       Date:  2004-05       Impact factor: 7.450

8.  Long-term results after inferior vena caval resection during retroperitoneal lymphadenectomy for metastatic germ cell cancer.

Authors:  S D Beck; S G Lalka
Journal:  J Vasc Surg       Date:  1998-11       Impact factor: 4.268

9.  Late relapse of testicular cancer.

Authors:  J Baniel; R S Foster; R Gonin; J E Messemer; J P Donohue; L H Einhorn
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

10.  Incidence, histology and management of intraluminal thrombus at post-chemotherapy retroperitoneal lymph node dissection.

Authors:  Paul Johnston; Stephen D W Beck; Liang Cheng; Timothy A Masterson; Richard Bihrle; Kenneth Kesler; Richard S Foster
Journal:  J Urol       Date:  2013-03-19       Impact factor: 7.450

View more
  4 in total

Review 1.  [Limits of surgery in uro-oncology].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2018-09       Impact factor: 0.639

2.  Locoregional surgical treatment improves the prognosis in patients with primary metastatic testicular cancer with a single bone or brain metastasis.

Authors:  Mierxiati Abudurexiti; Yao Zhu; Ding-Wei Ye
Journal:  Mol Clin Oncol       Date:  2020-06-03

3.  Preservation of Ejaculatory Function After Postchemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND) in Patients With Testicular Cancer: Template vs. Bilateral Resection.

Authors:  Andreas Hiester; Alessandro Nini; Anna Fingerhut; Robert Große Siemer; Christian Winter; Peter Albers; Achim Lusch
Journal:  Front Surg       Date:  2019-01-17

Review 4.  Major complications of post-chemotherapy retroperitoneal lymph node dissection in a contemporary cohort of patients with testicular cancer and a review of the literature.

Authors:  Christian Guido Ruf; Simon Krampe; Cord Matthies; Petra Anheuser; Tim Nestler; Jörg Simon; Hendrik Isbarn; Klaus Peter Dieckmann
Journal:  World J Surg Oncol       Date:  2020-09-24       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.